Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
PJ-34
60
CHF
CHF 60.00
In stock
AG-CR1-0100-M0011 mgCHF 60.00
AG-CR1-0100-M0055 mgCHF 95.00
AG-CR1-0100-M02525 mgCHF 200.00
| Product Details | |
|---|---|
| Synonyms | N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide . HCl |
| Product Type | Chemical |
| Properties | |
| Formula |
C17H17N3O2 . HCl |
| MW | 295.2 . 36.5 |
| CAS | 344458-15-7 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to light brown powder. |
| Solubility | Soluble in DMSO or water. |
| Identity | Identity determined by 1H-NMR and MS. |
| InChi Key | RURAZZMDMNRXMI-UHFFFAOYSA-N |
| Smiles | Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Hygroscopic. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor.
- Inhibits peroxynitrite-induced cell necrosis.
- Shows significant, dose-dependent anti-inflammatory effects in a variety of local inflammation models.
- Provides cardioprotection by decreasing myocardial infarct size.
- Shows protective effects in models of stroke.
- Suppresses cell growth in liver cancer cells.
Product References
- Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation: F. Garcia Soriano, et al.; Nat. Med. 7, 108 (2001)
- Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke: G.E. Abdelkarim, et al.; Int. J. Mol. Med. 7, 255 (2001)
- Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase: J.G. Mabley, et al.; Inflamm. Res. 50, 561 (2001)
- Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure: P. Pacher, et al.; J. Am. Coll. Cardiol. 40, 1006 (2002)
- Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents: P. Jagtap, et al.; Crit. Care Med. 30, 1071 (2002)
- Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor: R. Faro, et al.; Ann. Thorac. Surg. 73, 575 (2002)
- PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells: Oncol. Rep. 20, 567 (2008)
- The role of PARP activation in glutamate-induced necroptosis in HT-22 cells: X. Xu, et al.; Brain Res. 1343, 206 (2010)
- Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway: R. Vaschetto, et al.; Crit. Care 14, R45 (2010)
- Effect of parthanatos on ropivacaine-induced damage in SH-SY5Y cells: T. Zheng, et al.; Clin. Exp. Pharmacol. Physiol. 44, 586 (2017)